Journal of Drugs in Dermatology (JDD) Breaking News: Double-Blind Irradiation Study of a Novel Topical Product (TPF 50) Finds Indications for Prevention of Sun Damage Associated with Skin Aging and Non-Melanoma Skin Cancer (NMSC)

Released: 4-Mar-2014 8:00 AM EST
Source Newsroom: Journal of Drugs in Dermatology
Contact Information

Available for logged-in reporters only

Citations Journal of Drugs in Dermatology (JDD), March 2014

Newswise — NEW YORK, March 4, 2014 -- Journal of Drugs in Dermatology (JDD) today released a clinical study highlighting the efficacy of Triple Protection Factor Broad Spectrum Sunscreen, TPF 50, to prevent skin sun damage and Non-Melanoma Skin Cancer (NMSC). In this head-to-head comparison study, investigators Enzo Emanuele MD, PhD, James M. Spencer MD, MS and Martin Braun MD found that TPF50 was more effective than both the main DNA repair and AO existing products.

Continued exposure to ultraviolet radiation (UVR) is one of the major risk factors for photo-aging and the development of non-melanoma skin cancer (NMSC). Mainstream sunscreens cannot ensure a complete protection against all molecular lesions associated with UVR exposure, making the emergence of TPF 50 a significant advance in preventive science.

"JDD offers one of the fastest routes for disseminating dermatologic information. The JDD is pleased to publish this relevant, timely breakthrough research for dermatologists. This new information is important, very beneficial and is another treatment in the dermatologist's armamentarium in preventing skin cancers," said Dr. Robins, Editor-in-Chief and Professor Emeritus of Dermatology at New York University School of Medicine.

The study entitled, An Experimental Double-Blind Irradiation Study of a Novel Topical Product (TPF 50) Compared to Other Topical Products With DNA Repair Enzymes, Antioxidants, and Growth Factors With Sunscreens: Implications for Preventing Skin Aging and Cancer, is featured in the March issue of JDD, Volume 13, Issue 3 – Special Topics at AAD - with expanded distribution at the American Academy of Dermatology annual conference on March 21, 2014 in Denver, Colorado. You may pick up your complimentary JDD issue at our AAD booth, as well as accessing the article here.

About Journal of Drugs in Dermatology (JDD)
The Journal of Drugs in Dermatology (JDD) is a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®. Founded by the renowned Dr. Perry Robins, MD and now in its 12th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology. JDD presents original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology. Articles are reviewed by an International Editorial Board of over 150 renowned experts. JDD reaches around 14,500 dermatology healthcare professionals and has been recognized as the official publication of the International Society of Dermatologic Surgery (ISDS) and the Orlando Dermatology Aesthetic and Clinical (ODAC) Conference. Visit JDDonline.com for article archives, access to CME activities, supplements and author instructions. For more information, visit JDDonline.com.


Comment/Share